What does this research mean for the field?

Concurrent chemoradiotherapy with daily low-dose carboplatin provides durable disease control and acceptable toxicity in older patients with unresectable locally advanced non-small-cell lung cancer. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to assess the efficacy and safety of concurrent chemoradiotherapy with low-dose carboplatin in older patients with unresectable lung cancer and identify prognostic indicators.

February 28, 2026Current OncologyOpen Access

Concurrent Chemoradiotherapy with Daily Low-Dose Carboplatin in Older Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer: Clinical Outcomes and Prognostic Significance of Systemic Inflammation Markers

View Full Paper

Ask AI

Bookmark

Authors

YMY. MiuraSaitama International Medical Center HIH. ImaiSaitama International Medical Center SESatoshi EndoGunma Children's Medical Center

Discussion

Member takes

Implication

This retrospective evaluation shows improved overall survival in older patients with unresectable lung cancer, suggesting critical prognostic factors.

Key Points

This research aims to assess the efficacy and safety of concurrent chemoradiotherapy with low-dose carboplatin in older patients with unresectable lung cancer and identify prognostic indicators.
Retrospective evaluation of 52 older patients with locally advanced NSCLC.
Assessments included clinical outcomes of concurrent chemoradiotherapy with daily low-dose carboplatin.
Multivariate analysis to determine prognostic significance of systemic inflammation markers.
Median progression-free survival (PFS) was 11.5 months.
Median overall survival (OS) was 40.1 months.
The Glasgow Prognostic Score (GPS) was identified as an independent predictor of PFS.
A GPS of 0–1 correlated with significantly longer OS.

Cite This Study

Miura et al. (2026) studied this question.

synapsesocial.com/papers/69a286eb0a974eb0d3c0234e https://doi.org/10.3390/curroncol33030135

View Full Paper

Ask AI

Bookmark

Implication

This retrospective evaluation shows improved overall survival in older patients with unresectable lung cancer, suggesting critical prognostic factors.

Concurrent Chemoradiotherapy with Daily Low-Dose Carboplatin in Older Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer: Clinical Outcomes and Prognostic Significance of Systemic Inflammation Markers

Discussion

Member takes

Implication

Key Points

Cite This Study

Concurrent Chemoradiotherapy with Daily Low-Dose Carboplatin in Older Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer: Clinical Outcomes and Prognostic Significance of Systemic Inflammation Markers

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider